National Cancer Institute: SBIR Phase II Bridge Awards for Cancer Therapies and Imaging Technologies

Opportunity ID: 43576

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-CA-08-021
Funding Opportunity Title: SBIR Phase II Bridge Awards to Accelerate the Development of New Cancer Therapies and Cancer Imaging Technologies Toward Commercialization (SBIR [R44])
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.394 — Cancer Detection and Diagnosis Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Dec 03, 2008
Last Updated Date: Dec 04, 2008
Original Closing Date for Applications: Feb 27, 2009
Current Closing Date for Applications: Feb 27, 2009
Archive Date: Mar 30, 2009
Estimated Total Program Funding: $10,000,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Small businesses
Additional Information on Eligibility:

Additional Information

Agency Name: National Institutes of Health
Description: Purpose. This Funding Opportunity Announcement (FOA), launched as a pilot initiative at the National Institutes of Health (NIH) by the National Cancer Institute (NCI), solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional NIH funding to support the next stage of development for previously-funded NIH SBIR Phase II projects applicable to cancer therapies and cancer imaging technologies. The purpose of this FOA is to address the funding gap known as the Valley of Death between the end of the SBIR Phase II award and the commercialization stage. This FOA is also designed to promote partnerships between NIHs SBIR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital intensive steps that are required to commercialize new products/technologies emerging from NIH-funded SBIR Phase II projects. Applicants responding to this FOA must provide a specific commercialization plan that includes details on any independent third-party investor funding that has already been secured or is anticipated. It is expected that the level of this independent third-party funding will equal or exceed the NCI funds being requested throughout the Phase II Bridge Award project period. NCI support is thus intended to benefit cancer patients by accelerating the development of new cancer therapies (including anticancer agents and oncological therapeutic devices) and imaging devices/technologies toward commercialization. Only applications proposing projects in these areas will be considered responsive. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as needed but are not required.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-021.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
ADOBE-FORMS-A Adobe-Forms-A PKG00008952 Dec 03, 2008 Mar 06, 2009 View

Package 1

Mandatory forms

43576 RR_SF424-1.1.pdf

43576 RR_KeyPersonExpanded-1.1.pdf

43576 RR_OtherProjectInfo-1.1.pdf

43576 RR_PerformanceSite-1.1.pdf

43576 RR_Budget-1.1.pdf

43576 SBIR_STTR_Information-1.0.pdf

43576 PHS398_CoverPageSupplement-1.1.pdf

43576 PHS398_ResearchPlan-1.1.pdf

43576 PHS398_Checklist-1.1.pdf

Optional forms

43576 PHS398_CoverLetter-1.1.pdf

43576 RR_SubawardBudget-1.2.pdf


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *